|
1
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang J, Jiang Y, Liang H, Li P, Xiao H, Ji
J, Xiang W, Shi JF, Fan YG, Li L, et al: Attributable causes of
cancer in China. Ann Oncol. 23:2983–2999. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scagliotti GV, De Marinis F, Rinaldi M,
Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla
G, et al: Phase III randomized trial comparing three platinum-based
doublets in advanced non-small-cell lung cancer. J Clin Oncol.
20:4285–4291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mendelsohn J and Baselga J: Status of
epidermal growth factor receptor antagonists in the biology and
treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller VA, Kris MG, Shah N, Patel J,
Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, et al:
Bronchioloalveolar pathologic subtype and smoking history predict
sensitivity to gefitinib in advanced non-small-cell lung cancer. J
Clin Oncol. 22:1103–1109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gervas P, Ivanova A, Vasiliev N, Ananina
O, Zharkova O, Rogovieva O, Verzhbitskaya N, Didichuk I,
Cheremisina O, Popova N, et al: Frequency of EGFR mutations in
non-small cell lung cancer patients: Screening data from west
siberia. Asian Pac J Cancer Prev. 16:689–792. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chao TT, Wang CY, Lai CC, Chen YL, Tsai
YT, Chen PT, Lin HI, Huang YC, Shiau CW, Yu CJ and Chen KF: TD-19,
an erlotinib derivative, induces epidermal growth factor receptor
wild-type nonsmall-cell lung cancer apoptosis through
CIP2A-mediated pathway. J Pharmacol Exp Ther. 351:352–358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Linardou H, Dahabreh IJ, Bafaloukos D,
Kosmidis P and Murray S: Somatic EGFR mutations and efficacy of
tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 6:352–366.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Helena AY, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gandhi J, Zhang J, Xie Y, Soh J,
Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW,
et al: Alterations in genes of the EGFR signaling pathway and their
relationship to EGFR tyrosine kinase inhibitor sensitivity in lung
cancer cell lines. PLoS One. 4:e45762009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fan XX, Wong MP, Cao ZW, Li N, Wu JL, Zhou
H, Jiang Z, Liu L and Leung E: Abstract 3193: Apoptotic effect of a
single compound derived from natural product in Gefitinib-resistant
non-small cell lung cancer cells. Cancer Res. 74:2014. View Article : Google Scholar
|
|
13
|
Chikan NA, Bhavaniprasad V, Anbarasu K,
Shabir N and Patel TN: From natural products to drugs for
epimutation computer-aided drug design. Appl Biochem Biotechnol.
170:164–175. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wood ER, Truesdale AT, McDonald OB, Yuan
D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K,
et al: A unique structure for epidermal growth factor receptor
bound to GW572016 (Lapatinib) Relationships among protein
conformation, inhibitor off-rate, and receptor activity in tumor
cells. Cancer Res. 64:6652–6659. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guex N and Peitsch MC: SWISS-MODEL and the
Swiss-PdbViewer: An environment for comparative protein modeling.
Electrophoresis. 18:2714–2723. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Trott O and Olson AJ: AutoDock Vina:
Improving the speed and accuracy of docking with a new scoring
function, efficient optimization, and multithreading. J Comput
Chem. 31:455–461. 2010.PubMed/NCBI
|
|
17
|
Seeliger D and de Groot BL: Ligand docking
and binding site analysis with PyMOL and Autodock/Vina. J Comput
Aided Mol Des. 24:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morris GM, Huey R, Lindstrom W, Sanner MF,
Belew RK, Goodsell DS and Olson AJ: AutoDock4 and AutoDockTools4:
Automated docking with selective receptor flexibility. J Comput
Chem. 30:2785–2791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lipinski CA, Lombardo F, Dominy BW and
Feeney PJ: Experimental and computational approaches to estimate
solubility and permeability in drug discovery and development
settings. Adv Drug Deliv Rev. 46:3–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:2070–2075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bae GS, Kim MS, Park KC, Koo BS, Jo IJ,
Choi SB, Lee DS, Kim YC, Kim TH, Seo SW, et al: Effect of
biologically active fraction of Nardostachys jatamansi on
cerulein-induced acute pancreatitis. World J Gastroenterol.
18:3223–3234. 2012.PubMed/NCBI
|
|
22
|
Li W, Shi J, Li Q, Duan HH and Tang MK:
Nardosinone reduces neuronal injury induced by oxygen-glucose
deprivation in primary cortical cultures. Yao Xue Xue Bao.
48:1422–1429. 2013.(In Chinese). PubMed/NCBI
|
|
23
|
Ju SM, Lee J, Kang JG, Jeong SO, Park JH,
Pae HO, Lee GS, Kim WS, Lyu YS and Jeon BH: Nardostachys chinensis
induces granulocytic differentiation with the suppression of cell
growth through p27(Kip1) protein-related G0/G1 phase arrest in
human promyelocytic leukemic cells. Pharm Biol. 53:1002–1009. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
More SV, Koppula S, Kim IS, Kumar H, Kim
BW and Choi DK: The role of bioactive compounds on the promotion of
neurite outgrowth. Molecules. 17:6728–6753. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ahmad A, Sattar MZ, Rathore HA, Fatima T,
Khan SA, Afzal S, Lazhari M, Ahmed FU and Eseyin O: Pharmacological
importance of Nardostachys jatamansi DC: A potential therapeutic
agent in different pathological ailments. J Chem Pharmaceutical
Res. 5:431–438. 2013.
|
